Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026)

InMed Pharmaceuticals has reported Operating Leases over the past 5 years, most recently at $123827.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 76.6% year-over-year to $123827.0; the TTM value through Dec 2025 reached $123827.0, down 76.6%, while the annual FY2025 figure was $305755.0, 52.59% down from the prior year.
  • Operating Leases for Q4 2025 was $123827.0 at InMed Pharmaceuticals, down from $215478.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $1.2 million in Q4 2023 and troughed at $15994.0 in Q2 2023.
  • A 5-year average of $427640.2 and a median of $305755.0 in 2025 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: plummeted 95.89% in 2023 and later skyrocketed 3931.92% in 2024.
  • Year by year, Operating Leases stood at $825427.0 in 2021, then plummeted by 77.72% to $183902.0 in 2022, then soared by 534.56% to $1.2 million in 2023, then crashed by 54.65% to $529248.0 in 2024, then plummeted by 76.6% to $123827.0 in 2025.
  • Business Quant data shows Operating Leases for INM at $123827.0 in Q4 2025, $215478.0 in Q3 2025, and $305755.0 in Q2 2025.